Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | hypocretin (orexin) receptor 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | hypocretin (orexin) receptor 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Echinococcus granulosus | sex peptide receptor | hypocretin (orexin) receptor 1 | 425 aa | 350 aa | 23.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | pyruvate dehydrogenase | 0.023 | 0.9145 | 0.8825 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0244 | 1 | 1 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.0244 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.023 | 0.9145 | 0.8825 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0244 | 1 | 1 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0244 | 1 | 1 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0244 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0099 | 0.0855 | 1 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0244 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0244 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.31691 uM | PUBCHEM_BIOASSAY: Homogeneous Time Resolved Fluorescence (HTRF)-based cell-based high throughput dose response assay for antagonists of the orexin 1 receptor (OX1R; HCRTR1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID434989, AID435008, AID463079, AID485270, AID492963, AID492964, AID492965, AID493232, AID504717, AID504718] | ChEMBL. | No reference |
IC50 (functional) | 1.77 uM | PUBCHEM_BIOASSAY: Counterscreen assay for antagonists of the orexin 1 receptor (OX1R; HCRTR1): Homogeneous Time Resolved Fluorescence (HTRF)-based cell-based dose response assay for antagonists of the orexin 2 receptor (OX2R; HCRTR2), run by assay provider. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | = 5.93 uM | PUBCHEM_BIOASSAY: Fluorescence-based cell-based high throughput dose response assay for antagonists of the orexin 1 receptor (OX1R; HCRTR1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID434989, AID435008, AID463079, AID485270, AID492963, AID492964, AID492965, AID493232, AID504717, AID504718] | ChEMBL. | No reference |
IC50 (functional) | 29 uM | PUBCHEM_BIOASSAY: Counterscreen assay for antagonists of the orexin 1 receptor (OX1R; HCRTR1): Fluorescence-based cell-based dose response assay for antagonists of the orexin 2 receptor (OX2R; HCRTR2), run by assay provider. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.